Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Abasaglar® (insulin glargine): use in patients with COVID-19 (coronavirus disease 2019)
The use of Abasaglar in patients with COVID-19 has not been studied.
Use of Abasaglar in a Patient With COVID-19
COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1
Lilly has not studied the use of Abasaglar in patients with COVID-19 nor in patients at risk of contracting COVID-19.
According to the label, respiratory infections are not listed as a warning or precautions for use of Abasaglar.2
Clinicians should use their clinical judgment to determine the most appropriate approach to use Abasaglar in a patient who has confirmed or suspected COVID-19.
Infectious Disease Resources for COVID-19
For current information on COVID-19, please refer to
-
Coronavirus disease (COVID-19) outbreak on the regional office EU WHO
-
Coronavirus disease (COVID-19) outbreak: guidance for people with diabetes on the IDF website, and
1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
2. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
3. Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19
4. International Diabetes Federation Europe. COVID-19 outbreak: guidance for people with diabetes. https://www.idf.org/our-network/regions-members/europe/europe-news/196-information-on-corona-virus-disease-2019-covid-19-outbreak-and-guidance-for-people-with-diabetes.html. Accessed March 18, 2020
5. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china
Glossary
Abasaglar = Abasaglar® (insulin glargine) 100 units/mL
COVID-19 = coronavirus disease 2019
ECDC = European Centre for Disease Prevention and Control
EU WHO = World Health Organization (European regional office)
Lilly = Eli Lilly and Company
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
Date of Last Review: 17 March 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays